FMC Corporation (FMC) Q1 2026 earnings review
Volume Returns, But Profitability Continues to Crater
FMC's Q1 2026 results highlight a company in deep structural transition. While volume improved (+2%) and drove revenue to $759 million (beating guidance), the bottom line suffered a massive blow. Adjusted EBITDA collapsed 40% year-over-year to just $72 million as generic competition forced a 6% price reduction, compounded by rising tariffs and raw material costs. With Q1 free cash flow hitting negative $628 million and a GAAP net loss of $281 million, the balance sheet remains under extreme pressure. Management reaffirmed full-year guidance and continues its dual-track process: executing a standalone turnaround while actively evaluating a sale of the entire company.
🐂 Bull Case
Sales of new active ingredients doubled year-over-year in Q1. The company expects these products to generate $300 to $400 million in FY26 (up 75%+ YoY), proving the R&D pipeline can successfully commercialize.
Volume improved 2% globally, with EMEA revenue up 12% to $307 million and North America up 6% to $198 million, signaling an end to the brutal destocking phase in these regions.
🐻 Bear Case
The combination of forced price cuts (-6%) to compete with generic diamides, new tariffs, and high raw material costs destroyed Q1 profitability. Adjusted EBITDA fell 40% on just a 4% revenue drop.
Q1 free cash flow was negative $628 million. With FY26 guidance projecting breakeven FCF at best (-$65M to $65M), the company has virtually no margin for error in its $1 billion debt reduction plan.
⚖️ Verdict: 🔴
Bearish. The inflection in volume is a positive leading indicator, but the structural damage to FMC's pricing power and margins is severe. The heavy reliance on a steep back-half 2026 recovery creates significant execution risk.
Key Themes
Generics Destroying Pricing Power
Pricing declined 6% in Q1, firmly in line with the ongoing narrative of generic CTPR entering the market. FMC has been forced to lower basic formulation prices to defend market share for its Rynaxypyr and legacy core portfolios, particularly in Latin America.
Tariffs and Raw Materials Squeeze Margins
Management explicitly cited tariffs and unfavorable raw material costs as primary drivers for the 40% collapse in Q1 Adjusted EBITDA. This contradicts the cost-favorability tailwinds FMC enjoyed in late 2025 and suggests a more difficult operating environment for the legacy portfolio.
New Active Ingredients Accelerating
The long-term bull thesis rests entirely on the innovation pipeline. Sales of new active ingredients (like Isoflex, fluindapyr, and Dodhylex) doubled YoY in Q1. FMC expects this portfolio to reach $300-$400 million in FY26, representing over 75% growth and acting as the sole offset to generic erosion.
Strategic Review Remains Open
FMC confirmed it is actively evaluating 'multiple options' in its Board-authorized strategic review, which includes a potential sale of the company. This runs parallel to its standalone plan of reducing debt by $1 billion and divesting the India business.
Other KPIs
Worsened from -$596 million in Q1 2025. While Q1 is historically a period of working capital build, the $32 million YoY deterioration was driven entirely by lower cash from operations. This places immense pressure on H2 collections.
A severe deterioration compared to the -$15.5 million loss in Q1 2025. This was driven primarily by non-cash tax charges related to valuation allowances, alongside lower operating earnings, higher restructuring costs, and increased interest expense.
Guidance
Decelerating. Implies a 17% YoY decline at the midpoint vs Q2 2025 ($1.05B). Exacerbated by a 5% headwind from the exclusion of the India business and mid-single-digit price declines from generic pressure.
Decelerating. Represents a 32% collapse at the midpoint compared to $206.5 million in Q2 2025, heavily impacted by negative operating leverage and price give-backs.
Stable. The company maintained its prior full-year guidance, representing a 17% decline from FY25. Achieving this requires a massive acceleration in H2 (guided at $468-$508M vs $202-$222M in H1).
Stable compared to previous guidance, but implies roughly breakeven cash generation for the year. This heightens the reliance on asset sales (like the India divestiture) to achieve the stated $1 billion debt reduction target.
Key Questions
H2 Execution Risk
Your guidance implies H2 Adjusted EBITDA must more than double compared to H1. Given the persistent pricing pressure and new tariff headwinds, what structural cost reductions give you confidence in hitting this steep ramp?
Tariff and Raw Material Permanence
Q1 profitability was hit by tariffs and raw material cost inflation. Are these costs expected to remain elevated throughout 2026, and how much ability do you have to push price to offset them in a generic-heavy market?
Strategic Review Timeline
With the Board actively evaluating strategic alternatives, is there a targeted timeline for concluding this process, and how is the uncertainty affecting customer contracting and employee retention?